Daniel E. Johnson

18.4k total citations · 6 hit papers
133 papers, 13.6k citations indexed

About

Daniel E. Johnson is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Daniel E. Johnson has authored 133 papers receiving a total of 13.6k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Molecular Biology, 55 papers in Oncology and 27 papers in Cancer Research. Recurrent topics in Daniel E. Johnson's work include Cytokine Signaling Pathways and Interactions (25 papers), Cell death mechanisms and regulation (25 papers) and NF-κB Signaling Pathways (18 papers). Daniel E. Johnson is often cited by papers focused on Cytokine Signaling Pathways and Interactions (25 papers), Cell death mechanisms and regulation (25 papers) and NF-κB Signaling Pathways (18 papers). Daniel E. Johnson collaborates with scholars based in United States, Canada and China. Daniel E. Johnson's co-authors include Jennifer R. Grandis, Lewis T. Williams, Rachel A. O’Keefe, Julie E. Bauman, Vivian Wai Yan Lui, C. René Leemans, Barbara Burtness, L T Williams, Sabine Werner and Shivendra V. Singh and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Daniel E. Johnson

129 papers receiving 13.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Head and neck squamous cell carcinoma

2020 2.5k citations Daniel E. Johnson, Julie E. Bauman et al. profile →
Targeting the IL-6/JAK/STAT3 signalling axis in cancer

2018 2.2k citations Daniel E. Johnson, Rachel A. O’Keefe et al. profile →
Structural and Functional Diversity in the FGf Receptor Multigene Family

1992 1.1k citations Daniel E. Johnson et al. profile →
SIGNALLING BY RECEPTOR TYROSINE KINASES

1993 894 citations Daniel E. Johnson et al. profile →
Purification and Complementary DNA Cloning of a Receptor for Basic Fibroblast Growth Factor

1989 578 citations Daniel E. Johnson et al. profile →
Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesisin vivo

2000 509 citations Jennifer R. Grandis, Daniel E. Johnson et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Daniel E. Johnson	8.4k	4.3k	2.3k	2.2k	1.5k	133	13.6k
Vassilis G. Gorgoulis	11.6k 1.4×	5.4k 1.2×	3.2k 1.4×	2.0k 0.9×	1.7k 1.1×	331	18.5k
Yi-Xin Zeng	6.8k 0.8×	3.6k 0.8×	3.8k 1.7×	1.8k 0.8×	703 0.5×	183	11.3k
Mu‐Sheng Zeng	6.8k 0.8×	4.2k 1.0×	4.0k 1.8×	1.6k 0.7×	575 0.4×	297	11.7k
Walter N. Hittelman	7.4k 0.9×	3.8k 0.9×	2.5k 1.1×	984 0.5×	510 0.3×	223	12.2k
Alexandra Giatromanolaki	7.6k 0.9×	4.2k 1.0×	5.9k 2.6×	2.0k 0.9×	714 0.5×	389	15.3k
Dennis E. Hallahan	6.5k 0.8×	3.2k 0.7×	1.9k 0.8×	1.3k 0.6×	592 0.4×	267	13.3k
Thierry Soussi	7.5k 0.9×	7.9k 1.8×	3.2k 1.4×	1.2k 0.5×	609 0.4×	174	13.1k
Weiya Xia	12.4k 1.5×	8.0k 1.8×	3.8k 1.7×	2.4k 1.1×	1.3k 0.8×	114	18.0k
Andres J. Klein–Szanto	12.0k 1.4×	7.0k 1.6×	4.9k 2.2×	1.7k 0.8×	2.6k 1.7×	383	21.3k
Michael I. Koukourakis	6.1k 0.7×	3.9k 0.9×	5.0k 2.2×	1.1k 0.5×	558 0.4×	332	13.0k

Countries citing papers authored by Daniel E. Johnson

Since Specialization

Citations

This map shows the geographic impact of Daniel E. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel E. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel E. Johnson more than expected).

Fields of papers citing papers by Daniel E. Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel E. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel E. Johnson. The network helps show where Daniel E. Johnson may publish in the future.

Co-authorship network of co-authors of Daniel E. Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel E. Johnson. A scholar is included among the top collaborators of Daniel E. Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel E. Johnson. Daniel E. Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Na’ara, Shorook, Zhibin Cui, Becky Xu Hua Fu, et al.. (2025). Neddylation as a target in PIK3CA-mutated head and neck cancer. Biochemical and Biophysical Research Communications. 759. 151703–151703. 1 indexed citations

Luo, Ying, Chao Wang, Daniel E. Johnson, et al.. (2025). A regularized‐multi‐field optimization algorithm for robust IMPT. Medical Physics. 52(8). e18046–e18046.

Na’ara, Shorook, et al.. (2025). Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors. Molecular Cancer Therapeutics. 24(6). 931–941.

Borah, Ashir A., et al.. (2025). Human Papilloma Virus Does Not Fully Inactivate p53 Cellular Activity in HNSCC. Head & Neck. 48(3). 863–875.

Grandis, Jennifer R., Katherine A. Skorupski, Ning Cheng, et al.. (2025). Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer. Cancer Cell. 43(11). 2051–2068.e9. 2 indexed citations

Johnson, Daniel E., H. Harold Li, & Bruce F. Kimler. (2024). Dosimetry: Was and Is an Absolute Requirement for Quality Radiation Research. Radiation Research. 202(2). 102–129. 5 indexed citations

Zeng, Yan, Jose Rivera, Ning Cheng, et al.. (2022). STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer. Clinical Cancer Research. 28(21). 4737–4746. 19 indexed citations

Grandis, Jennifer R., et al.. (2022). The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer. Advances in Biological Regulation. 87. 100934–100934. 9 indexed citations

Cui, Zhibin, et al.. (2021). Caspase-8 mutations associated with head and neck cancer differentially retain functional properties related to TRAIL-induced apoptosis and cytokine induction. Cell Death and Disease. 12(8). 775–775. 17 indexed citations

10.

Izumi, Hiroki, Zhiyong Wang, Yusuke Goto, et al.. (2020). Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer. Molecular Cancer Therapeutics. 19(7). 1562–1571. 24 indexed citations

11.

Brand, Toni M., Stefan Hartmann, Neil E. Bhola, et al.. (2018). Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. Cancer Research. 78(9). 2383–2395. 31 indexed citations

12.

Farooqui, Mariya, et al.. (2018). STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non–Small Cell Lung Cancer. Molecular Cancer Therapeutics. 17(9). 1917–1926. 34 indexed citations

13.

Redner, Robert L., Jan H. Beumer, Patricia Kropf, et al.. (2018). A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. Leukemia & lymphoma. 59(11). 2595–2601. 10 indexed citations

14.

Peyser, Noah D., Lin Wang, Yan Zeng, et al.. (2016). STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma. Cancer Prevention Research. 9(8). 657–663. 11 indexed citations

15.

Bauman, Julie E., Yan Zang, Malabika Sen, et al.. (2016). Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane. Cancer Prevention Research. 9(7). 547–557. 85 indexed citations

16.

Brand, Toni M., Stefan Hartmann, Neil E. Bhola, et al.. (2016). Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients. Clinical Cancer Research. 23(12). 3072–3083. 44 indexed citations

17.

Sen, Malabika, Sonali Joyce, Changyou Li, et al.. (2012). Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer. Clinical Cancer Research. 18(18). 4986–4996. 128 indexed citations

18.

Zang, Yan, Sufi M. Thomas, Elena T. Chan, et al.. (2012). Carfilzomib and ONX 0912 Inhibit Cell Survival and Tumor Growth of Head and Neck Cancer and Their Activities Are Enhanced by Suppression of Mcl-1 or Autophagy. Clinical Cancer Research. 18(20). 5639–5649. 66 indexed citations

19.

Li, Changyou, Yan Zang, Malabika Sen, et al.. (2009). Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. Molecular Cancer Therapeutics. 8(8). 2211–2220. 46 indexed citations

20.

Li, Changyou, Rongxiu Li, Jennifer R. Grandis, & Daniel E. Johnson. (2008). Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. Molecular Cancer Therapeutics. 7(6). 1647–1655. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact